Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) Stock Competitors & Peer Comparison
See IRWD's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for IRWD and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| IRWD | $4.44 | +4.35% | 702.9M | 5.47 | $0.78 | N/A |
| TAK | $18.40 | +2.02% | 57.2B | 12.93 | $1.39 | +3.46% |
| HLN | $9.98 | -0.55% | 44.4B | 18.80 | $0.54 | +1.23% |
| TEVA | $37.30 | +2.35% | 42B | 12.30 | $2.93 | N/A |
| ZTS | $77.51 | +0.53% | 32.4B | 11.74 | $6.58 | +2.71% |
| VTRS | $17.06 | +3.33% | 19.4B | 6.60 | $2.52 | +2.89% |
| ITCI | $131.87 | +0.00% | 14B | -180.64 | -$0.73 | N/A |
| ELAN | $24.66 | +3.09% | 11.9B | 22.56 | $1.06 | N/A |
| CTLT | $63.48 | +0.00% | 11.5B | -27.84 | -$2.28 | N/A |
| RDY | $12.15 | +0.12% | 10.1B | 19.93 | $0.61 | +0.68% |
Stock Comparison
Takeda Pharmaceutical Company Limited (NYSE: TAK)
IRWD vs TAK Comparison September 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 702.9M. In comparison, TAK has a market cap of 57.2B. Regarding current trading prices, IRWD is priced at $4.44 on the NASDAQ, while TAK trades at $18.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 5.47, whereas TAK's P/E ratio is 12.93. In terms of profitability, IRWD's ROE is -0.57%, compared to TAK's ROE of +0.02%. Regarding short-term risk, IRWD is more volatile compared to TAK. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check TAK's competition here
Haleon plc (NYSE: HLN)
IRWD vs HLN Comparison September 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 702.9M. In comparison, HLN has a market cap of 44.4B. Regarding current trading prices, IRWD is priced at $4.44 on the NASDAQ, while HLN trades at $9.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 5.47, whereas HLN's P/E ratio is 18.80. In terms of profitability, IRWD's ROE is -0.57%, compared to HLN's ROE of +0.17%. Regarding short-term risk, IRWD is more volatile compared to HLN. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check HLN's competition here
Teva Pharmaceutical Industries Limited (NYSE: TEVA)
IRWD vs TEVA Comparison September 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 702.9M. In comparison, TEVA has a market cap of 42B. Regarding current trading prices, IRWD is priced at $4.44 on the NASDAQ, while TEVA trades at $37.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 5.47, whereas TEVA's P/E ratio is 12.30. In terms of profitability, IRWD's ROE is -0.57%, compared to TEVA's ROE of +0.09%. Regarding short-term risk, IRWD is less volatile compared to TEVA. This indicates lower risk in terms of short-term price fluctuations for IRWD.Check TEVA's competition here
Zoetis Inc. (NYSE: ZTS)
IRWD vs ZTS Comparison September 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 702.9M. In comparison, ZTS has a market cap of 32.4B. Regarding current trading prices, IRWD is priced at $4.44 on the NASDAQ, while ZTS trades at $77.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 5.47, whereas ZTS's P/E ratio is 11.74. In terms of profitability, IRWD's ROE is -0.57%, compared to ZTS's ROE of +0.69%. Regarding short-term risk, IRWD is more volatile compared to ZTS. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check ZTS's competition here
Viatris Inc. (NASDAQ: VTRS)
IRWD vs VTRS Comparison September 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 702.9M. In comparison, VTRS has a market cap of 19.4B. Regarding current trading prices, IRWD is priced at $4.44 on the NASDAQ, while VTRS trades at $17.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 5.47, whereas VTRS's P/E ratio is 6.60. In terms of profitability, IRWD's ROE is -0.57%, compared to VTRS's ROE of -0.03%. Regarding short-term risk, IRWD is more volatile compared to VTRS. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check VTRS's competition here
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI)
IRWD vs ITCI Comparison September 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 702.9M. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, IRWD is priced at $4.44 on the NASDAQ, while ITCI trades at $131.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 5.47, whereas ITCI's P/E ratio is -180.64. In terms of profitability, IRWD's ROE is -0.57%, compared to ITCI's ROE of -0.09%. Regarding short-term risk, IRWD is more volatile compared to ITCI. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check ITCI's competition here
Elanco Animal Health Incorporated (NYSE: ELAN)
IRWD vs ELAN Comparison September 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 702.9M. In comparison, ELAN has a market cap of 11.9B. Regarding current trading prices, IRWD is priced at $4.44 on the NASDAQ, while ELAN trades at $24.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 5.47, whereas ELAN's P/E ratio is 22.56. In terms of profitability, IRWD's ROE is -0.57%, compared to ELAN's ROE of -0.03%. Regarding short-term risk, IRWD is more volatile compared to ELAN. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check ELAN's competition here
Catalent, Inc. (NYSE: CTLT)
IRWD vs CTLT Comparison September 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 702.9M. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, IRWD is priced at $4.44 on the NASDAQ, while CTLT trades at $63.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 5.47, whereas CTLT's P/E ratio is -27.84. In terms of profitability, IRWD's ROE is -0.57%, compared to CTLT's ROE of -0.25%. Regarding short-term risk, IRWD is more volatile compared to CTLT. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check CTLT's competition here
Dr. Reddy's Laboratories Limited (NYSE: RDY)
IRWD vs RDY Comparison September 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 702.9M. In comparison, RDY has a market cap of 10.1B. Regarding current trading prices, IRWD is priced at $4.44 on the NASDAQ, while RDY trades at $12.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 5.47, whereas RDY's P/E ratio is 19.93. In terms of profitability, IRWD's ROE is -0.57%, compared to RDY's ROE of +0.09%. Regarding short-term risk, IRWD is more volatile compared to RDY. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check RDY's competition here
Alkermes plc (NASDAQ: ALKS)
IRWD vs ALKS Comparison September 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 702.9M. In comparison, ALKS has a market cap of 7.9B. Regarding current trading prices, IRWD is priced at $4.44 on the NASDAQ, while ALKS trades at $47.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 5.47, whereas ALKS's P/E ratio is 49.68. In terms of profitability, IRWD's ROE is -0.57%, compared to ALKS's ROE of +0.04%. Regarding short-term risk, IRWD is more volatile compared to ALKS. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check ALKS's competition here
Lantheus Holdings, Inc. (NASDAQ: LNTH)
IRWD vs LNTH Comparison September 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 702.9M. In comparison, LNTH has a market cap of 6.6B. Regarding current trading prices, IRWD is priced at $4.44 on the NASDAQ, while LNTH trades at $100.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 5.47, whereas LNTH's P/E ratio is 16.95. In terms of profitability, IRWD's ROE is -0.57%, compared to LNTH's ROE of +0.23%. Regarding short-term risk, IRWD is more volatile compared to LNTH. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check LNTH's competition here
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX)
IRWD vs AMRX Comparison September 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 702.9M. In comparison, AMRX has a market cap of 5.6B. Regarding current trading prices, IRWD is priced at $4.44 on the NASDAQ, while AMRX trades at $18.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 5.47, whereas AMRX's P/E ratio is 19.64. In terms of profitability, IRWD's ROE is -0.57%, compared to AMRX's ROE of -3.27%. Regarding short-term risk, IRWD is more volatile compared to AMRX. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check AMRX's competition here
Indivior Pharmaceuticals Inc (NASDAQ: INDV)
IRWD vs INDV Comparison September 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 702.9M. In comparison, INDV has a market cap of 4.3B. Regarding current trading prices, IRWD is priced at $4.44 on the NASDAQ, while INDV trades at $34.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 5.47, whereas INDV's P/E ratio is 9.47. In terms of profitability, IRWD's ROE is -0.57%, compared to INDV's ROE of -2.16%. Regarding short-term risk, IRWD is more volatile compared to INDV. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check INDV's competition here
Alvotech (NASDAQ: ALVOW)
IRWD vs ALVOW Comparison September 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 702.9M. In comparison, ALVOW has a market cap of 3B. Regarding current trading prices, IRWD is priced at $4.44 on the NASDAQ, while ALVOW trades at $0.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 5.47, whereas ALVOW's P/E ratio is 47.36. In terms of profitability, IRWD's ROE is -0.57%, compared to ALVOW's ROE of +0.77%. Regarding short-term risk, IRWD is less volatile compared to ALVOW. This indicates lower risk in terms of short-term price fluctuations for IRWD.Check ALVOW's competition here
Regencell Bioscience Holdings Limited (NASDAQ: RGC)
IRWD vs RGC Comparison September 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 702.9M. In comparison, RGC has a market cap of 2.7B. Regarding current trading prices, IRWD is priced at $4.44 on the NASDAQ, while RGC trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 5.47, whereas RGC's P/E ratio is -387.32. In terms of profitability, IRWD's ROE is -0.57%, compared to RGC's ROE of -2.32%. Regarding short-term risk, IRWD is less volatile compared to RGC. This indicates lower risk in terms of short-term price fluctuations for IRWD.Check RGC's competition here
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN)
IRWD vs SUPN Comparison September 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 702.9M. In comparison, SUPN has a market cap of 2.5B. Regarding current trading prices, IRWD is priced at $4.44 on the NASDAQ, while SUPN trades at $43.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 5.47, whereas SUPN's P/E ratio is 14.29. In terms of profitability, IRWD's ROE is -0.57%, compared to SUPN's ROE of -0.10%. Regarding short-term risk, IRWD is more volatile compared to SUPN. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check SUPN's competition here
Bausch Health Companies Inc. (NYSE: BHC)
IRWD vs BHC Comparison September 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 702.9M. In comparison, BHC has a market cap of 2.4B. Regarding current trading prices, IRWD is priced at $4.44 on the NASDAQ, while BHC trades at $6.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 5.47, whereas BHC's P/E ratio is 1.65. In terms of profitability, IRWD's ROE is -0.57%, compared to BHC's ROE of +0.89%. Regarding short-term risk, IRWD is more volatile compared to BHC. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check BHC's competition here
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH)
IRWD vs DCPH Comparison September 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 702.9M. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, IRWD is priced at $4.44 on the NASDAQ, while DCPH trades at $25.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 5.47, whereas DCPH's P/E ratio is -11.58. In terms of profitability, IRWD's ROE is -0.57%, compared to DCPH's ROE of -0.56%. Regarding short-term risk, IRWD is more volatile compared to DCPH. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check DCPH's competition here
Avadel Pharmaceuticals plc (NASDAQ: AVDL)
IRWD vs AVDL Comparison September 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 702.9M. In comparison, AVDL has a market cap of 2.1B. Regarding current trading prices, IRWD is priced at $4.44 on the NASDAQ, while AVDL trades at $21.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 5.47, whereas AVDL's P/E ratio is -1082.00. In terms of profitability, IRWD's ROE is -0.57%, compared to AVDL's ROE of +0.05%. Regarding short-term risk, IRWD is more volatile compared to AVDL. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check AVDL's competition here
HUTCHMED (China) Limited (NASDAQ: HCM)
IRWD vs HCM Comparison September 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 702.9M. In comparison, HCM has a market cap of 2.1B. Regarding current trading prices, IRWD is priced at $4.44 on the NASDAQ, while HCM trades at $12.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 5.47, whereas HCM's P/E ratio is 4.46. In terms of profitability, IRWD's ROE is -0.57%, compared to HCM's ROE of +0.01%. Regarding short-term risk, IRWD is more volatile compared to HCM. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check HCM's competition here
Trulieve Cannabis Corp. (NYSE: TRLV)
IRWD vs TRLV Comparison September 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 702.9M. In comparison, TRLV has a market cap of 2B. Regarding current trading prices, IRWD is priced at $4.44 on the NASDAQ, while TRLV trades at $12.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 5.47, whereas TRLV's P/E ratio is -4.78. In terms of profitability, IRWD's ROE is -0.57%, compared to TRLV's ROE of -0.44%. Regarding short-term risk, IRWD is less volatile compared to TRLV. This indicates lower risk in terms of short-term price fluctuations for IRWD.Check TRLV's competition here
Perrigo Company plc (NYSE: PRGO)
IRWD vs PRGO Comparison September 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 702.9M. In comparison, PRGO has a market cap of 2B. Regarding current trading prices, IRWD is priced at $4.44 on the NASDAQ, while PRGO trades at $14.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 5.47, whereas PRGO's P/E ratio is 5.77. In terms of profitability, IRWD's ROE is -0.57%, compared to PRGO's ROE of -0.56%. Regarding short-term risk, IRWD is more volatile compared to PRGO. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check PRGO's competition here
Embecta Corp. (NASDAQ: EMBCV)
IRWD vs EMBCV Comparison September 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 702.9M. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, IRWD is priced at $4.44 on the NASDAQ, while EMBCV trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 5.47, whereas EMBCV's P/E ratio is N/A. In terms of profitability, IRWD's ROE is -0.57%, compared to EMBCV's ROE of -0.19%. Regarding short-term risk, IRWD is less volatile compared to EMBCV. This indicates lower risk in terms of short-term price fluctuations for IRWD.Check EMBCV's competition here
Dynavax Technologies Corporation (NASDAQ: DVAX)
IRWD vs DVAX Comparison September 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 702.9M. In comparison, DVAX has a market cap of 1.8B. Regarding current trading prices, IRWD is priced at $4.44 on the NASDAQ, while DVAX trades at $15.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 5.47, whereas DVAX's P/E ratio is -41.89. In terms of profitability, IRWD's ROE is -0.57%, compared to DVAX's ROE of -0.10%. Regarding short-term risk, IRWD is more volatile compared to DVAX. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check DVAX's competition here
Alvotech (NASDAQ: ALVO)
IRWD vs ALVO Comparison September 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 702.9M. In comparison, ALVO has a market cap of 1.8B. Regarding current trading prices, IRWD is priced at $4.44 on the NASDAQ, while ALVO trades at $5.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 5.47, whereas ALVO's P/E ratio is -15.41. In terms of profitability, IRWD's ROE is -0.57%, compared to ALVO's ROE of +0.77%. Regarding short-term risk, IRWD is more volatile compared to ALVO. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check ALVO's competition here
Eton Pharmaceuticals, Inc. (NASDAQ: ETON)
IRWD vs ETON Comparison September 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 702.9M. In comparison, ETON has a market cap of 1.7B. Regarding current trading prices, IRWD is priced at $4.44 on the NASDAQ, while ETON trades at $60.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 5.47, whereas ETON's P/E ratio is 131.37. In terms of profitability, IRWD's ROE is -0.57%, compared to ETON's ROE of +0.40%. Regarding short-term risk, IRWD is less volatile compared to ETON. This indicates lower risk in terms of short-term price fluctuations for IRWD.Check ETON's competition here
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP)
IRWD vs ANIP Comparison September 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 702.9M. In comparison, ANIP has a market cap of 1.6B. Regarding current trading prices, IRWD is priced at $4.44 on the NASDAQ, while ANIP trades at $73.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 5.47, whereas ANIP's P/E ratio is 8.75. In terms of profitability, IRWD's ROE is -0.57%, compared to ANIP's ROE of +0.19%. Regarding short-term risk, IRWD is more volatile compared to ANIP. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check ANIP's competition here
Taro Pharmaceutical Industries Ltd. (NYSE: TARO)
IRWD vs TARO Comparison September 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 702.9M. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, IRWD is priced at $4.44 on the NASDAQ, while TARO trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 5.47, whereas TARO's P/E ratio is 30.05. In terms of profitability, IRWD's ROE is -0.57%, compared to TARO's ROE of +0.03%. Regarding short-term risk, IRWD is more volatile compared to TARO. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check TARO's competition here
Phibro Animal Health Corporation (NASDAQ: PAHC)
IRWD vs PAHC Comparison September 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 702.9M. In comparison, PAHC has a market cap of 1.6B. Regarding current trading prices, IRWD is priced at $4.44 on the NASDAQ, while PAHC trades at $40.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 5.47, whereas PAHC's P/E ratio is 13.10. In terms of profitability, IRWD's ROE is -0.57%, compared to PAHC's ROE of +0.29%. Regarding short-term risk, IRWD is less volatile compared to PAHC. This indicates lower risk in terms of short-term price fluctuations for IRWD.Check PAHC's competition here
Harrow Health, Inc. (NASDAQ: HROW)
IRWD vs HROW Comparison September 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 702.9M. In comparison, HROW has a market cap of 1.4B. Regarding current trading prices, IRWD is priced at $4.44 on the NASDAQ, while HROW trades at $38.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 5.47, whereas HROW's P/E ratio is -37.34. In terms of profitability, IRWD's ROE is -0.57%, compared to HROW's ROE of -1.04%. Regarding short-term risk, IRWD is less volatile compared to HROW. This indicates lower risk in terms of short-term price fluctuations for IRWD.Check HROW's competition here
Cronos Group Inc. (NASDAQ: CRON)
IRWD vs CRON Comparison September 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 702.9M. In comparison, CRON has a market cap of 1.3B. Regarding current trading prices, IRWD is priced at $4.44 on the NASDAQ, while CRON trades at $3.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 5.47, whereas CRON's P/E ratio is 32.10. In terms of profitability, IRWD's ROE is -0.57%, compared to CRON's ROE of +0.06%. Regarding short-term risk, IRWD is more volatile compared to CRON. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check CRON's competition here
Pacira BioSciences, Inc. (NASDAQ: PCRX)
IRWD vs PCRX Comparison September 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 702.9M. In comparison, PCRX has a market cap of 1B. Regarding current trading prices, IRWD is priced at $4.44 on the NASDAQ, while PCRX trades at $26.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 5.47, whereas PCRX's P/E ratio is 10.18. In terms of profitability, IRWD's ROE is -0.57%, compared to PCRX's ROE of +0.02%. Regarding short-term risk, IRWD is more volatile compared to PCRX. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check PCRX's competition here
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH)
IRWD vs AMPH Comparison September 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 702.9M. In comparison, AMPH has a market cap of 1B. Regarding current trading prices, IRWD is priced at $4.44 on the NASDAQ, while AMPH trades at $23.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 5.47, whereas AMPH's P/E ratio is 7.84. In terms of profitability, IRWD's ROE is -0.57%, compared to AMPH's ROE of +0.10%. Regarding short-term risk, IRWD is more volatile compared to AMPH. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check AMPH's competition here
PetIQ, Inc. (NASDAQ: PETQ)
IRWD vs PETQ Comparison September 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 702.9M. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, IRWD is priced at $4.44 on the NASDAQ, while PETQ trades at $30.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 5.47, whereas PETQ's P/E ratio is 83.73. In terms of profitability, IRWD's ROE is -0.57%, compared to PETQ's ROE of +0.01%. Regarding short-term risk, IRWD is more volatile compared to PETQ. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check PETQ's competition here
Collegium Pharmaceutical, Inc. (NASDAQ: COLL)
IRWD vs COLL Comparison September 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 702.9M. In comparison, COLL has a market cap of 778.4M. Regarding current trading prices, IRWD is priced at $4.44 on the NASDAQ, while COLL trades at $24.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 5.47, whereas COLL's P/E ratio is 3.01. In terms of profitability, IRWD's ROE is -0.57%, compared to COLL's ROE of +0.16%. Regarding short-term risk, IRWD is more volatile compared to COLL. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check COLL's competition here
Glass House Brands Inc (NYSE: GLAS)
IRWD vs GLAS Comparison September 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 702.9M. In comparison, GLAS has a market cap of 657.7M. Regarding current trading prices, IRWD is priced at $4.44 on the NASDAQ, while GLAS trades at $8.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 5.47, whereas GLAS's P/E ratio is -15.18. In terms of profitability, IRWD's ROE is -0.57%, compared to GLAS's ROE of -0.51%. Regarding short-term risk, IRWD is more volatile compared to GLAS. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check GLAS's competition here
Aquestive Therapeutics, Inc. (NASDAQ: AQST)
IRWD vs AQST Comparison September 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 702.9M. In comparison, AQST has a market cap of 657.4M. Regarding current trading prices, IRWD is priced at $4.44 on the NASDAQ, while AQST trades at $5.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 5.47, whereas AQST's P/E ratio is -8.06. In terms of profitability, IRWD's ROE is -0.57%, compared to AQST's ROE of +2.44%. Regarding short-term risk, IRWD is more volatile compared to AQST. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check AQST's competition here
Evotec SE (NASDAQ: EVO)
IRWD vs EVO Comparison September 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 702.9M. In comparison, EVO has a market cap of 639.4M. Regarding current trading prices, IRWD is priced at $4.44 on the NASDAQ, while EVO trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 5.47, whereas EVO's P/E ratio is -2.54. In terms of profitability, IRWD's ROE is -0.57%, compared to EVO's ROE of -0.27%. Regarding short-term risk, IRWD is more volatile compared to EVO. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check EVO's competition here
Evolus, Inc. (NASDAQ: EOLS)
IRWD vs EOLS Comparison September 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 702.9M. In comparison, EOLS has a market cap of 598M. Regarding current trading prices, IRWD is priced at $4.44 on the NASDAQ, while EOLS trades at $8.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 5.47, whereas EOLS's P/E ratio is -28.75. In terms of profitability, IRWD's ROE is -0.57%, compared to EOLS's ROE of +1.23%. Regarding short-term risk, IRWD is more volatile compared to EOLS. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check EOLS's competition here
BioDelivery Sciences International, Inc. (NASDAQ: BDSI)
IRWD vs BDSI Comparison September 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 702.9M. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, IRWD is priced at $4.44 on the NASDAQ, while BDSI trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 5.47, whereas BDSI's P/E ratio is 6.82. In terms of profitability, IRWD's ROE is -0.57%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, IRWD is more volatile compared to BDSI. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check BDSI's competition here
Tilray Brands, Inc. (NASDAQ: TLRY)
IRWD vs TLRY Comparison September 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 702.9M. In comparison, TLRY has a market cap of 503.2M. Regarding current trading prices, IRWD is priced at $4.44 on the NASDAQ, while TLRY trades at $4.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 5.47, whereas TLRY's P/E ratio is -4.15. In terms of profitability, IRWD's ROE is -0.57%, compared to TLRY's ROE of -0.08%. Regarding short-term risk, IRWD is more volatile compared to TLRY. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check TLRY's competition here
Kamada Ltd. (NASDAQ: KMDA)
IRWD vs KMDA Comparison September 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 702.9M. In comparison, KMDA has a market cap of 483.5M. Regarding current trading prices, IRWD is priced at $4.44 on the NASDAQ, while KMDA trades at $8.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 5.47, whereas KMDA's P/E ratio is 22.05. In terms of profitability, IRWD's ROE is -0.57%, compared to KMDA's ROE of +0.08%. Regarding short-term risk, IRWD is more volatile compared to KMDA. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check KMDA's competition here
Canopy Growth Corporation (NASDAQ: CGC)
IRWD vs CGC Comparison September 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 702.9M. In comparison, CGC has a market cap of 411.6M. Regarding current trading prices, IRWD is priced at $4.44 on the NASDAQ, while CGC trades at $0.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 5.47, whereas CGC's P/E ratio is -0.59. In terms of profitability, IRWD's ROE is -0.57%, compared to CGC's ROE of -0.33%. Regarding short-term risk, IRWD is more volatile compared to CGC. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check CGC's competition here
Alpha Teknova, Inc. (NASDAQ: TKNO)
IRWD vs TKNO Comparison September 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 702.9M. In comparison, TKNO has a market cap of 379.6M. Regarding current trading prices, IRWD is priced at $4.44 on the NASDAQ, while TKNO trades at $7.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 5.47, whereas TKNO's P/E ratio is -22.84. In terms of profitability, IRWD's ROE is -0.57%, compared to TKNO's ROE of -0.25%. Regarding short-term risk, IRWD is less volatile compared to TKNO. This indicates lower risk in terms of short-term price fluctuations for IRWD.Check TKNO's competition here
Emergent BioSolutions Inc. (NYSE: EBS)
IRWD vs EBS Comparison September 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 702.9M. In comparison, EBS has a market cap of 320.9M. Regarding current trading prices, IRWD is priced at $4.44 on the NASDAQ, while EBS trades at $6.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 5.47, whereas EBS's P/E ratio is 4.32. In terms of profitability, IRWD's ROE is -0.57%, compared to EBS's ROE of -0.36%. Regarding short-term risk, IRWD is more volatile compared to EBS. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check EBS's competition here
Alimera Sciences, Inc. (NASDAQ: ALIM)
IRWD vs ALIM Comparison September 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 702.9M. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, IRWD is priced at $4.44 on the NASDAQ, while ALIM trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 5.47, whereas ALIM's P/E ratio is 5.28. In terms of profitability, IRWD's ROE is -0.57%, compared to ALIM's ROE of -1.59%. Regarding short-term risk, IRWD is more volatile compared to ALIM. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check ALIM's competition here
Landec Corporation (NASDAQ: LNDC)
IRWD vs LNDC Comparison September 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 702.9M. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, IRWD is priced at $4.44 on the NASDAQ, while LNDC trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 5.47, whereas LNDC's P/E ratio is -4.04. In terms of profitability, IRWD's ROE is -0.57%, compared to LNDC's ROE of +6.44%. Regarding short-term risk, IRWD is more volatile compared to LNDC. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check LNDC's competition here
Aurora Cannabis Inc. (NASDAQ: ACB)
IRWD vs ACB Comparison September 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 702.9M. In comparison, ACB has a market cap of 250.9M. Regarding current trading prices, IRWD is priced at $4.44 on the NASDAQ, while ACB trades at $4.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 5.47, whereas ACB's P/E ratio is -8.27. In terms of profitability, IRWD's ROE is -0.57%, compared to ACB's ROE of -0.21%. Regarding short-term risk, IRWD is more volatile compared to ACB. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check ACB's competition here
Cardiol Therapeutics Inc. (NASDAQ: CRDL)
IRWD vs CRDL Comparison September 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 702.9M. In comparison, CRDL has a market cap of 247.8M. Regarding current trading prices, IRWD is priced at $4.44 on the NASDAQ, while CRDL trades at $2.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 5.47, whereas CRDL's P/E ratio is -8.57. In terms of profitability, IRWD's ROE is -0.57%, compared to CRDL's ROE of -1.94%. Regarding short-term risk, IRWD is less volatile compared to CRDL. This indicates lower risk in terms of short-term price fluctuations for IRWD.Check CRDL's competition here
SIGA Technologies, Inc. (NASDAQ: SIGA)
IRWD vs SIGA Comparison September 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 702.9M. In comparison, SIGA has a market cap of 232.4M. Regarding current trading prices, IRWD is priced at $4.44 on the NASDAQ, while SIGA trades at $3.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 5.47, whereas SIGA's P/E ratio is 12.00. In terms of profitability, IRWD's ROE is -0.57%, compared to SIGA's ROE of -0.02%. Regarding short-term risk, IRWD is more volatile compared to SIGA. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check SIGA's competition here
Shineco, Inc. (NASDAQ: TYHT)
IRWD vs TYHT Comparison September 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 702.9M. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, IRWD is priced at $4.44 on the NASDAQ, while TYHT trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 5.47, whereas TYHT's P/E ratio is -1.61. In terms of profitability, IRWD's ROE is -0.57%, compared to TYHT's ROE of -0.57%. Regarding short-term risk, IRWD is less volatile compared to TYHT. This indicates lower risk in terms of short-term price fluctuations for IRWD.Check TYHT's competition here
Organogenesis Holdings Inc. (NASDAQ: ORGO)
IRWD vs ORGO Comparison September 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 702.9M. In comparison, ORGO has a market cap of 209.7M. Regarding current trading prices, IRWD is priced at $4.44 on the NASDAQ, while ORGO trades at $1.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 5.47, whereas ORGO's P/E ratio is 54.33. In terms of profitability, IRWD's ROE is -0.57%, compared to ORGO's ROE of -0.24%. Regarding short-term risk, IRWD is less volatile compared to ORGO. This indicates lower risk in terms of short-term price fluctuations for IRWD.Check ORGO's competition here
Journey Medical Corporation (NASDAQ: DERM)
IRWD vs DERM Comparison September 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 702.9M. In comparison, DERM has a market cap of 208.3M. Regarding current trading prices, IRWD is priced at $4.44 on the NASDAQ, while DERM trades at $7.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 5.47, whereas DERM's P/E ratio is -20.46. In terms of profitability, IRWD's ROE is -0.57%, compared to DERM's ROE of -0.20%. Regarding short-term risk, IRWD is more volatile compared to DERM. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check DERM's competition here
Recro Pharma, Inc. (NASDAQ: REPH)
IRWD vs REPH Comparison September 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 702.9M. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, IRWD is priced at $4.44 on the NASDAQ, while REPH trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 5.47, whereas REPH's P/E ratio is -8.04. In terms of profitability, IRWD's ROE is -0.57%, compared to REPH's ROE of -0.22%. Regarding short-term risk, IRWD is less volatile compared to REPH. This indicates lower risk in terms of short-term price fluctuations for IRWD.Check REPH's competition here
Organigram Global Inc. (NASDAQ: OGI)
IRWD vs OGI Comparison September 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 702.9M. In comparison, OGI has a market cap of 166.1M. Regarding current trading prices, IRWD is priced at $4.44 on the NASDAQ, while OGI trades at $1.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 5.47, whereas OGI's P/E ratio is 2.65. In terms of profitability, IRWD's ROE is -0.57%, compared to OGI's ROE of +0.21%. Regarding short-term risk, IRWD is more volatile compared to OGI. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check OGI's competition here
Lifecore Biomedical, Inc. (NASDAQ: LFCR)
IRWD vs LFCR Comparison September 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 702.9M. In comparison, LFCR has a market cap of 164.7M. Regarding current trading prices, IRWD is priced at $4.44 on the NASDAQ, while LFCR trades at $4.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 5.47, whereas LFCR's P/E ratio is -4.10. In terms of profitability, IRWD's ROE is -0.57%, compared to LFCR's ROE of -2.51%. Regarding short-term risk, IRWD is less volatile compared to LFCR. This indicates lower risk in terms of short-term price fluctuations for IRWD.Check LFCR's competition here
Theratechnologies Inc. (NASDAQ: THTX)
IRWD vs THTX Comparison September 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 702.9M. In comparison, THTX has a market cap of 155.9M. Regarding current trading prices, IRWD is priced at $4.44 on the NASDAQ, while THTX trades at $3.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 5.47, whereas THTX's P/E ratio is -28.83. In terms of profitability, IRWD's ROE is -0.57%, compared to THTX's ROE of +0.17%. Regarding short-term risk, IRWD is more volatile compared to THTX. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check THTX's competition here
Assertio Holdings, Inc. (NASDAQ: ASRT)
IRWD vs ASRT Comparison September 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 702.9M. In comparison, ASRT has a market cap of 151.9M. Regarding current trading prices, IRWD is priced at $4.44 on the NASDAQ, while ASRT trades at $23.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 5.47, whereas ASRT's P/E ratio is -7.10. In terms of profitability, IRWD's ROE is -0.57%, compared to ASRT's ROE of -0.39%. Regarding short-term risk, IRWD is more volatile compared to ASRT. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check ASRT's competition here
Societal CDMO, Inc. (NASDAQ: SCTL)
IRWD vs SCTL Comparison September 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 702.9M. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, IRWD is priced at $4.44 on the NASDAQ, while SCTL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 5.47, whereas SCTL's P/E ratio is -7.86. In terms of profitability, IRWD's ROE is -0.57%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, IRWD is more volatile compared to SCTL. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check SCTL's competition here
BGM Group Ltd. (NASDAQ: BGM)
IRWD vs BGM Comparison September 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 702.9M. In comparison, BGM has a market cap of 103.9M. Regarding current trading prices, IRWD is priced at $4.44 on the NASDAQ, while BGM trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 5.47, whereas BGM's P/E ratio is -0.94. In terms of profitability, IRWD's ROE is -0.57%, compared to BGM's ROE of -0.05%. Regarding short-term risk, IRWD is less volatile compared to BGM. This indicates lower risk in terms of short-term price fluctuations for IRWD.Check BGM's competition here
Procaps Group S.A. (NASDAQ: PROC)
IRWD vs PROC Comparison September 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 702.9M. In comparison, PROC has a market cap of 102.1M. Regarding current trading prices, IRWD is priced at $4.44 on the NASDAQ, while PROC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 5.47, whereas PROC's P/E ratio is 1.53. In terms of profitability, IRWD's ROE is -0.57%, compared to PROC's ROE of -2.22%. Regarding short-term risk, IRWD is more volatile compared to PROC. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check PROC's competition here
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX)
IRWD vs CPIX Comparison September 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 702.9M. In comparison, CPIX has a market cap of 98.3M. Regarding current trading prices, IRWD is priced at $4.44 on the NASDAQ, while CPIX trades at $6.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 5.47, whereas CPIX's P/E ratio is -16.40. In terms of profitability, IRWD's ROE is -0.57%, compared to CPIX's ROE of -0.47%. Regarding short-term risk, IRWD is less volatile compared to CPIX. This indicates lower risk in terms of short-term price fluctuations for IRWD.Check CPIX's competition here
OptiNose, Inc. (NASDAQ: OPTN)
IRWD vs OPTN Comparison September 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 702.9M. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, IRWD is priced at $4.44 on the NASDAQ, while OPTN trades at $9.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 5.47, whereas OPTN's P/E ratio is -4.42. In terms of profitability, IRWD's ROE is -0.57%, compared to OPTN's ROE of +0.34%. Regarding short-term risk, IRWD is more volatile compared to OPTN. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check OPTN's competition here
Zomedica Corp. (AMEX: ZOM)
IRWD vs ZOM Comparison September 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 702.9M. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, IRWD is priced at $4.44 on the NASDAQ, while ZOM trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 5.47, whereas ZOM's P/E ratio is -1.62. In terms of profitability, IRWD's ROE is -0.57%, compared to ZOM's ROE of -0.17%. Regarding short-term risk, IRWD is less volatile compared to ZOM. This indicates lower risk in terms of short-term price fluctuations for IRWD.Check ZOM's competition here
Upexi, Inc. (NASDAQ: GRVI)
IRWD vs GRVI Comparison September 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 702.9M. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, IRWD is priced at $4.44 on the NASDAQ, while GRVI trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 5.47, whereas GRVI's P/E ratio is 26.05. In terms of profitability, IRWD's ROE is -0.57%, compared to GRVI's ROE of -2.54%. Regarding short-term risk, IRWD is less volatile compared to GRVI. This indicates lower risk in terms of short-term price fluctuations for IRWD.Check GRVI's competition here
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT)
IRWD vs ZYBT Comparison September 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 702.9M. In comparison, ZYBT has a market cap of 78.2M. Regarding current trading prices, IRWD is priced at $4.44 on the NASDAQ, while ZYBT trades at $1.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 5.47, whereas ZYBT's P/E ratio is -7.50. In terms of profitability, IRWD's ROE is -0.57%, compared to ZYBT's ROE of -0.27%. Regarding short-term risk, IRWD is less volatile compared to ZYBT. This indicates lower risk in terms of short-term price fluctuations for IRWD.Check ZYBT's competition here
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE)
IRWD vs ZYNE Comparison September 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 702.9M. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, IRWD is priced at $4.44 on the NASDAQ, while ZYNE trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 5.47, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, IRWD's ROE is -0.57%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, IRWD is less volatile compared to ZYNE. This indicates lower risk in terms of short-term price fluctuations for IRWD.Check ZYNE's competition here
Silver Spike Investment Corp. (NASDAQ: SSIC)
IRWD vs SSIC Comparison September 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 702.9M. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, IRWD is priced at $4.44 on the NASDAQ, while SSIC trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 5.47, whereas SSIC's P/E ratio is 11.93. In terms of profitability, IRWD's ROE is -0.57%, compared to SSIC's ROE of +0.00%. Regarding short-term risk, IRWD is more volatile compared to SSIC. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check SSIC's competition here
InterCure Ltd. (NASDAQ: INCR)
IRWD vs INCR Comparison September 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 702.9M. In comparison, INCR has a market cap of 65.3M. Regarding current trading prices, IRWD is priced at $4.44 on the NASDAQ, while INCR trades at $5.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 5.47, whereas INCR's P/E ratio is -12.72. In terms of profitability, IRWD's ROE is -0.57%, compared to INCR's ROE of -0.09%. Regarding short-term risk, IRWD is less volatile compared to INCR. This indicates lower risk in terms of short-term price fluctuations for IRWD.Check INCR's competition here
The Valens Company Inc. (NASDAQ: VLNS)
IRWD vs VLNS Comparison September 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 702.9M. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, IRWD is priced at $4.44 on the NASDAQ, while VLNS trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 5.47, whereas VLNS's P/E ratio is -1.03. In terms of profitability, IRWD's ROE is -0.57%, compared to VLNS's ROE of N/A. Regarding short-term risk, IRWD is more volatile compared to VLNS. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check VLNS's competition here
Talphera, Inc. (NASDAQ: TLPH)
IRWD vs TLPH Comparison September 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 702.9M. In comparison, TLPH has a market cap of 61.2M. Regarding current trading prices, IRWD is priced at $4.44 on the NASDAQ, while TLPH trades at $1.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 5.47, whereas TLPH's P/E ratio is -3.81. In terms of profitability, IRWD's ROE is -0.57%, compared to TLPH's ROE of -0.87%. Regarding short-term risk, IRWD is more volatile compared to TLPH. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check TLPH's competition here
DURECT Corporation (NASDAQ: DRRX)
IRWD vs DRRX Comparison September 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 702.9M. In comparison, DRRX has a market cap of 59.3M. Regarding current trading prices, IRWD is priced at $4.44 on the NASDAQ, while DRRX trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 5.47, whereas DRRX's P/E ratio is -4.44. In terms of profitability, IRWD's ROE is -0.57%, compared to DRRX's ROE of -1.40%. Regarding short-term risk, IRWD is more volatile compared to DRRX. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check DRRX's competition here
Jupiter Wellness, Inc. (NASDAQ: JUPW)
IRWD vs JUPW Comparison September 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 702.9M. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, IRWD is priced at $4.44 on the NASDAQ, while JUPW trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 5.47, whereas JUPW's P/E ratio is -2.41. In terms of profitability, IRWD's ROE is -0.57%, compared to JUPW's ROE of -3.04%. Regarding short-term risk, IRWD is less volatile compared to JUPW. This indicates lower risk in terms of short-term price fluctuations for IRWD.Check JUPW's competition here
Qilian International Holding Group Limited (NASDAQ: QLI)
IRWD vs QLI Comparison September 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 702.9M. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, IRWD is priced at $4.44 on the NASDAQ, while QLI trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 5.47, whereas QLI's P/E ratio is -4.92. In terms of profitability, IRWD's ROE is -0.57%, compared to QLI's ROE of -0.16%. Regarding short-term risk, IRWD is more volatile compared to QLI. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check QLI's competition here
China Pharma Holdings, Inc. (AMEX: CPHI)
IRWD vs CPHI Comparison September 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 702.9M. In comparison, CPHI has a market cap of 35.8M. Regarding current trading prices, IRWD is priced at $4.44 on the NASDAQ, while CPHI trades at $0.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 5.47, whereas CPHI's P/E ratio is -2.06. In terms of profitability, IRWD's ROE is -0.57%, compared to CPHI's ROE of -0.17%. Regarding short-term risk, IRWD is more volatile compared to CPHI. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check CPHI's competition here
Rockwell Medical, Inc. (NASDAQ: RMTI)
IRWD vs RMTI Comparison September 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 702.9M. In comparison, RMTI has a market cap of 32.2M. Regarding current trading prices, IRWD is priced at $4.44 on the NASDAQ, while RMTI trades at $7.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 5.47, whereas RMTI's P/E ratio is -6.10. In terms of profitability, IRWD's ROE is -0.57%, compared to RMTI's ROE of -0.14%. Regarding short-term risk, IRWD is less volatile compared to RMTI. This indicates lower risk in terms of short-term price fluctuations for IRWD.Check RMTI's competition here
HEXO Corp. (NASDAQ: HEXO)
IRWD vs HEXO Comparison September 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 702.9M. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, IRWD is priced at $4.44 on the NASDAQ, while HEXO trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 5.47, whereas HEXO's P/E ratio is -0.26. In terms of profitability, IRWD's ROE is -0.57%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, IRWD is less volatile compared to HEXO. This indicates lower risk in terms of short-term price fluctuations for IRWD.Check HEXO's competition here
TherapeuticsMD, Inc. (NASDAQ: TXMD)
IRWD vs TXMD Comparison September 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 702.9M. In comparison, TXMD has a market cap of 25.1M. Regarding current trading prices, IRWD is priced at $4.44 on the NASDAQ, while TXMD trades at $2.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 5.47, whereas TXMD's P/E ratio is 110.55. In terms of profitability, IRWD's ROE is -0.57%, compared to TXMD's ROE of -0.01%. Regarding short-term risk, IRWD is more volatile compared to TXMD. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check TXMD's competition here
Aytu BioPharma, Inc. (NASDAQ: AYTU)
IRWD vs AYTU Comparison September 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 702.9M. In comparison, AYTU has a market cap of 24.1M. Regarding current trading prices, IRWD is priced at $4.44 on the NASDAQ, while AYTU trades at $2.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 5.47, whereas AYTU's P/E ratio is -1.17. In terms of profitability, IRWD's ROE is -0.57%, compared to AYTU's ROE of -1.49%. Regarding short-term risk, IRWD is more volatile compared to AYTU. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check AYTU's competition here
Cyclo Therapeutics, Inc. (NASDAQ: CYTH)
IRWD vs CYTH Comparison September 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 702.9M. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, IRWD is priced at $4.44 on the NASDAQ, while CYTH trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 5.47, whereas CYTH's P/E ratio is -0.80. In terms of profitability, IRWD's ROE is -0.57%, compared to CYTH's ROE of -7.30%. Regarding short-term risk, IRWD is more volatile compared to CYTH. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check CYTH's competition here
Evoke Pharma, Inc. (NASDAQ: EVOK)
IRWD vs EVOK Comparison September 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 702.9M. In comparison, EVOK has a market cap of 18.9M. Regarding current trading prices, IRWD is priced at $4.44 on the NASDAQ, while EVOK trades at $11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 5.47, whereas EVOK's P/E ratio is -7.97. In terms of profitability, IRWD's ROE is -0.57%, compared to EVOK's ROE of -0.89%. Regarding short-term risk, IRWD is more volatile compared to EVOK. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check EVOK's competition here
Optimi Health Corp. (NASDAQ: OPTH)
IRWD vs OPTH Comparison September 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 702.9M. In comparison, OPTH has a market cap of 16.1M. Regarding current trading prices, IRWD is priced at $4.44 on the NASDAQ, while OPTH trades at $4.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 5.47, whereas OPTH's P/E ratio is -18.26. In terms of profitability, IRWD's ROE is -0.57%, compared to OPTH's ROE of -0.90%. Regarding short-term risk, IRWD is more volatile compared to OPTH. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check OPTH's competition here
AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX)
IRWD vs ACRX Comparison September 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 702.9M. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, IRWD is priced at $4.44 on the NASDAQ, while ACRX trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 5.47, whereas ACRX's P/E ratio is -0.31. In terms of profitability, IRWD's ROE is -0.57%, compared to ACRX's ROE of -0.87%. Regarding short-term risk, IRWD is less volatile compared to ACRX. This indicates lower risk in terms of short-term price fluctuations for IRWD.Check ACRX's competition here
Caring Brands, Inc. (NASDAQ: CABR)
IRWD vs CABR Comparison September 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 702.9M. In comparison, CABR has a market cap of 12.4M. Regarding current trading prices, IRWD is priced at $4.44 on the NASDAQ, while CABR trades at $1.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 5.47, whereas CABR's P/E ratio is -2.43. In terms of profitability, IRWD's ROE is -0.57%, compared to CABR's ROE of -3.86%. Regarding short-term risk, IRWD is less volatile compared to CABR. This indicates lower risk in terms of short-term price fluctuations for IRWD.Check CABR's competition here
Agile Therapeutics, Inc. (NASDAQ: AGRX)
IRWD vs AGRX Comparison September 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 702.9M. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, IRWD is priced at $4.44 on the NASDAQ, while AGRX trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 5.47, whereas AGRX's P/E ratio is -0.89. In terms of profitability, IRWD's ROE is -0.57%, compared to AGRX's ROE of +1.32%. Regarding short-term risk, IRWD is less volatile compared to AGRX. This indicates lower risk in terms of short-term price fluctuations for IRWD.Check AGRX's competition here
Neoleukin Therapeutics, Inc. (NASDAQ: NLTX)
IRWD vs NLTX Comparison September 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 702.9M. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, IRWD is priced at $4.44 on the NASDAQ, while NLTX trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 5.47, whereas NLTX's P/E ratio is -0.28. In terms of profitability, IRWD's ROE is -0.57%, compared to NLTX's ROE of -0.45%. Regarding short-term risk, IRWD is less volatile compared to NLTX. This indicates lower risk in terms of short-term price fluctuations for IRWD.Check NLTX's competition here
Lannett Company, Inc. (NYSE: LCI)
IRWD vs LCI Comparison September 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 702.9M. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, IRWD is priced at $4.44 on the NASDAQ, while LCI trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 5.47, whereas LCI's P/E ratio is -0.04. In terms of profitability, IRWD's ROE is -0.57%, compared to LCI's ROE of +1.66%. Regarding short-term risk, IRWD is less volatile compared to LCI. This indicates lower risk in terms of short-term price fluctuations for IRWD.Check LCI's competition here
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP)
IRWD vs ADMP Comparison September 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 702.9M. In comparison, ADMP has a market cap of 7.3M. Regarding current trading prices, IRWD is priced at $4.44 on the NASDAQ, while ADMP trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 5.47, whereas ADMP's P/E ratio is -0.08. In terms of profitability, IRWD's ROE is -0.57%, compared to ADMP's ROE of -2.09%. Regarding short-term risk, IRWD is less volatile compared to ADMP. This indicates lower risk in terms of short-term price fluctuations for IRWD.Check ADMP's competition here
cbdMD, Inc. (AMEX: YCBD)
IRWD vs YCBD Comparison September 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 702.9M. In comparison, YCBD has a market cap of 5.2M. Regarding current trading prices, IRWD is priced at $4.44 on the NASDAQ, while YCBD trades at $0.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 5.47, whereas YCBD's P/E ratio is -1.22. In terms of profitability, IRWD's ROE is -0.57%, compared to YCBD's ROE of -0.34%. Regarding short-term risk, IRWD is less volatile compared to YCBD. This indicates lower risk in terms of short-term price fluctuations for IRWD.Check YCBD's competition here
Gelteq Limited Ordinary Shares (NASDAQ: GELS)
IRWD vs GELS Comparison September 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 702.9M. In comparison, GELS has a market cap of 5M. Regarding current trading prices, IRWD is priced at $4.44 on the NASDAQ, while GELS trades at $0.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 5.47, whereas GELS's P/E ratio is -1.08. In terms of profitability, IRWD's ROE is -0.57%, compared to GELS's ROE of -0.25%. Regarding short-term risk, IRWD is less volatile compared to GELS. This indicates lower risk in terms of short-term price fluctuations for IRWD.Check GELS's competition here
Mallinckrodt plc (AMEX: MNK)
IRWD vs MNK Comparison September 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 702.9M. In comparison, MNK has a market cap of 4.5M. Regarding current trading prices, IRWD is priced at $4.44 on the NASDAQ, while MNK trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 5.47, whereas MNK's P/E ratio is -0.44. In terms of profitability, IRWD's ROE is -0.57%, compared to MNK's ROE of -0.36%. Regarding short-term risk, IRWD is less volatile compared to MNK. This indicates lower risk in terms of short-term price fluctuations for IRWD.Check MNK's competition here
Flora Growth Corp. (NASDAQ: FLGC)
IRWD vs FLGC Comparison September 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 702.9M. In comparison, FLGC has a market cap of 4.2M. Regarding current trading prices, IRWD is priced at $4.44 on the NASDAQ, while FLGC trades at $7.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 5.47, whereas FLGC's P/E ratio is -0.19. In terms of profitability, IRWD's ROE is -0.57%, compared to FLGC's ROE of -3.03%. Regarding short-term risk, IRWD is less volatile compared to FLGC. This indicates lower risk in terms of short-term price fluctuations for IRWD.Check FLGC's competition here
Sunshine Biopharma, Inc. (NASDAQ: SBFM)
IRWD vs SBFM Comparison September 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 702.9M. In comparison, SBFM has a market cap of 2.7M. Regarding current trading prices, IRWD is priced at $4.44 on the NASDAQ, while SBFM trades at $1.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 5.47, whereas SBFM's P/E ratio is -0.19. In terms of profitability, IRWD's ROE is -0.57%, compared to SBFM's ROE of -0.24%. Regarding short-term risk, IRWD is more volatile compared to SBFM. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check SBFM's competition here
RedHill Biopharma Ltd. (NASDAQ: RDHL)
IRWD vs RDHL Comparison September 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 702.9M. In comparison, RDHL has a market cap of 2.7M. Regarding current trading prices, IRWD is priced at $4.44 on the NASDAQ, while RDHL trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 5.47, whereas RDHL's P/E ratio is 0.17. In terms of profitability, IRWD's ROE is -0.57%, compared to RDHL's ROE of +57.40%. Regarding short-term risk, IRWD is less volatile compared to RDHL. This indicates lower risk in terms of short-term price fluctuations for IRWD.Check RDHL's competition here
Universe Pharmaceuticals Inc. (NASDAQ: UPC)
IRWD vs UPC Comparison September 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 702.9M. In comparison, UPC has a market cap of 2.7M. Regarding current trading prices, IRWD is priced at $4.44 on the NASDAQ, while UPC trades at $4.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 5.47, whereas UPC's P/E ratio is -0.53. In terms of profitability, IRWD's ROE is -0.57%, compared to UPC's ROE of -0.03%. Regarding short-term risk, IRWD is less volatile compared to UPC. This indicates lower risk in terms of short-term price fluctuations for IRWD.Check UPC's competition here
PLx Pharma Inc. (NASDAQ: PLXP)
IRWD vs PLXP Comparison September 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 702.9M. In comparison, PLXP has a market cap of 2.5M. Regarding current trading prices, IRWD is priced at $4.44 on the NASDAQ, while PLXP trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 5.47, whereas PLXP's P/E ratio is -0.22. In terms of profitability, IRWD's ROE is -0.57%, compared to PLXP's ROE of -1.66%. Regarding short-term risk, IRWD is less volatile compared to PLXP. This indicates lower risk in terms of short-term price fluctuations for IRWD.Check PLXP's competition here
Athenex, Inc. (NASDAQ: ATNX)
IRWD vs ATNX Comparison September 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 702.9M. In comparison, ATNX has a market cap of 2.3M. Regarding current trading prices, IRWD is priced at $4.44 on the NASDAQ, while ATNX trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 5.47, whereas ATNX's P/E ratio is -0.02. In terms of profitability, IRWD's ROE is -0.57%, compared to ATNX's ROE of +0.22%. Regarding short-term risk, IRWD is more volatile compared to ATNX. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check ATNX's competition here
Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA)
IRWD vs SNOA Comparison September 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 702.9M. In comparison, SNOA has a market cap of 2.2M. Regarding current trading prices, IRWD is priced at $4.44 on the NASDAQ, while SNOA trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 5.47, whereas SNOA's P/E ratio is -1.09. In terms of profitability, IRWD's ROE is -0.57%, compared to SNOA's ROE of -0.46%. Regarding short-term risk, IRWD is more volatile compared to SNOA. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check SNOA's competition here
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH)
IRWD vs SHPH Comparison September 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRWD stands at 702.9M. In comparison, SHPH has a market cap of 2.1M. Regarding current trading prices, IRWD is priced at $4.44 on the NASDAQ, while SHPH trades at $3.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRWD currently has a P/E ratio of 5.47, whereas SHPH's P/E ratio is -0.17. In terms of profitability, IRWD's ROE is -0.57%, compared to SHPH's ROE of -4.08%. Regarding short-term risk, IRWD is more volatile compared to SHPH. This indicates higher risk in terms of short-term price fluctuations for IRWD.Check SHPH's competition here